Equities

Alzex Neuropharma Inc

TRRI:PKC

Alzex Neuropharma Inc

Actions
  • Price (USD)0.1988
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change-48.50%
  • Beta--
Data delayed at least 15 minutes, as of Jun 26 2024 19:54 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alzex Neuropharma Inc., formerly Trinity Resources Inc., is a biopharmaceutical company. The Company is engaged in research and development targeting treatments of brain diseases. It is also focused on chemical development of its new drugs dedicated to the symptomatic treatment of Alzheimer’s Disease but can be applied to other neurological diseases due to its platform technology.

  • Revenue in USD (TTM)0.00
  • Net income in USD-176.09k
  • Incorporated1971
  • Employees--
  • Location
    Alzex Neuropharma Inc2850 West Horizon Ridge, Suite 200HENDERSON 89052United StatesUSA
  • Phone+1 (310) 435-0435
  • Fax+1 (302) 421-5753
  • Websitehttps://trinresinc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sunvault Energy Inc3.90m-6.09m218.05k0.00------0.056-0.0552-0.05520.0339-0.02640.782922.757.36---132.14-81.52-----25.18---168.78-49.250.1722-4.78-----41.78---176.27------
Vector 21 Holdings Inc0.00-38.87k237.61k0.00---------0.023-0.0230.00-0.0730.00-------4,179.57-----------------28.67--------13.87------
Roth CH Acquisition Co0.007.54m243.08k--0.04830.0120.0323--6.406.400.0025.640.00------18.41--19.99--------------0.0405-------77.00------
Tocca Life Holdings Inc-100.00bn-100.00bn269.50k8.00---------------5,874.28----------------------------5.83-------90.68------
P2 Solar Inc-100.00bn-100.00bn292.17k0.00---------------0.0269--------------------------------------------
Alzex Neuropharma Inc0.00-176.09k299.25k-----------0.1309-0.13090.00-0.0816---------------------------12.16-----100.00--48.79------
Hallmark Venture Group Inc0.00-209.80k311.09k-----------0.0008-0.00080.00-0.0013------------------------------------32.39------
Trophy Resources Inc3.05m-5.13m314.95k80.00------0.1032-94.47-94.4731.24-0.09964.03--11.2238,150.00-677.10-499.42---1,483.13-2.56---168.05-3,024.140.3058--------32.81-232.76---59.06--
Trimax Corp-100.00bn-100.00bn320.21k-----------------0.0003------------------------0.0329--2.36--3.40--105.56------
Access-Power & Co Inc34.56k3.86k422.10k6.00105.002.10--12.210.000020.000020.00010.0010.1259------1.41--1.42--100.00--11.17------0.00--15.82--238.60------
Data as of Jun 26 2024. Currency figures normalised to Alzex Neuropharma Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.